Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of repeated intravitreal Lucentis injection by genotype in exudative age-related macular degeneration
KCT0002531Phase 4Completed
- Sponsor
- DNA Link
- Start
- Oct 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of ranibizumab in age-related macular degeneration (AMD), sponsored by DNA Link. Primary endpoint: Efficacy of repeated intravitreal Lucentis injections. Started Oct 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on KCT0002531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002531.